Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups
Tamoxifen is used worldwide to treat estrogen receptor-positive breast cancer. It is extensively metabolized, and minimum steady-state concentrations of its metabolite endoxifen (C<sub>SS,min ENDX</sub>) >5.97 ng/mL have been associated with favorable outcome. Endoxifen formation is m...
Main Authors: | Anna Mueller-Schoell, Robin Michelet, Lena Klopp-Schulze, Madelé van Dyk, Thomas E. Mürdter, Matthias Schwab, Markus Joerger, Wilhelm Huisinga, Gerd Mikus, Charlotte Kloft |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/10/2432 |
Similar Items
-
Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies
by: Anna Mueller-Schoell, et al.
Published: (2021-02-01) -
Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen
by: Lena Klopp-Schulze, et al.
Published: (2020-03-01) -
Clinical Trial: CYP2D6 Related Dose Escalation of Tamoxifen in Breast Cancer Patients With Iranian Ethnic Background Resulted in Increased Concentrations of Tamoxifen and Its Metabolites
by: Zahra Khalaj, et al.
Published: (2019-05-01) -
Unveiling the Impact of Morphine on Tamoxifen Metabolism in Mice in vivo
by: Florian Gabel, et al.
Published: (2020-02-01) -
Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen
by: Werner Schroth, et al.
Published: (2017-08-01)